CCM
CTIC

Consonance Capital Management’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Consonance Capital Management’s Portfolio CTIC Stock Details CTIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-2,512,800
Closed -$7.31M – 43
2021
Q1 		$7.31M Hold
2,512,800
– – 0.78% 25
2020
Q4 		$8.09M Buy
+2,512,800
New +$8.36M 0.76% 28
2016
Q1 		– Sell
-51,000
Closed -$635K – 29
2015
Q4 		$635K Buy
51,000
+5,000
+11% +$66.8K 0.09% 21
2015
Q3 		$672K Buy
+46,000
New +$795K 0.09% 28

Other funds holding CTIC

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
ACM
Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Consonance Capital Management's CTIC Position: Q2 2021 in Review

Consonance Capital Management sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2021, closing a stake of 2,512,800 shares — an estimated $7.31M sold.

Consonance Capital Management first reported a position in CTIC in Q3 2015 and held it in 4 quarters. The position peaked at $8.09M in Q4 2020. 50 funds tracked by Wall St. Rank hold CTIC as of Q2 2021.

  • Consonance Capital Management reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2021 after selling out during the quarter.
  • Consonance Capital Management sold 2,512,800 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2021, an estimated $7.31M.
  • Consonance Capital Management first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q3 2015 and held it in 4 quarters.
  • Consonance Capital Management's CTI BioPharma Corp. (DE) Common Stock position peaked at $8.09M in Q4 2020.
  • 50 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2021.

Based on Consonance Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.